Cancer Conversations™ in RCC: Improving Outcomes With Immunotherapy and Targeted Agents

Join us to hear insights on management of patients with advanced RCC, from first-line treatment through therapy after multiple lines of treatment, in this expert-led webinar discussion.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

Welcome and Introduction

Selecting Optimal First-Line Treatment in Advanced or Metastatic RCC

Treatment Approaches for Progressive RCC After 1 or More Previous Lines of Therapy

Final Thoughts

This webinar will feature a discussion-based platform with time to address audience questions throughout the program.

Faculty

Program Director
Elizabeth R. Plimack, MD, MS

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Faculty
Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Faculty
Brian Rini, MD, FASCO

Chief of Clinical Trials
Division of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Target Audience
This educational program is intended for medical and urologic oncologists and other healthcare professionals involved in the care of patients with RCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select first-line ICI-based combination treatment for individual patients with advanced or metastatic RCC, taking into consideration available clinical evidence, expert recommendations, and patient preferences
  • Recommend treatment options for patients with pretreated advanced RCC through multiple lines of therapy that consider prior treatment history and patient comorbidities
  • Manage specific disease-related complications or adverse events associated with immuno-oncology combinations for advanced RCC
  • Evaluate ongoing major clinical trials investigating novel therapeutic approaches in advanced or metastatic RCC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.